Irem Demiray
Research Subjects
Irem Demiray has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Tahir Yagdi
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
2 shared publications - Ahmet Daylan
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Anıl Ziya Apaydin
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Aysen Yaprak Engin
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Cagatay Engin
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Emrah Oguz
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication
Latest Publications
- Open Access
A Decade of Durable Mechanical Circulatory Support with HeartMate 3 Across Age Groups in a Single-Center Experience
Background: Long-term real-world data after HeartMate 3 implantation remain limited, particularly regarding age-specific outcomes. We evaluated on-device survival and major adverse events across nearly a decade of experience. Methods: This retrospective single-center study included 215 patients undergoing primary HeartMate 3 implantation between January 2016 and October 2025. On-device mortality was analyzed using Aalen–Johansen cumulative incidence estimates with heart transplantation as a competing event; age-group differences were assessed using Fine–Gray regression. Transplant-censored Kaplan–Meier survival was examined secondarily, and mortality predictors were evaluated using multivariable Cox regression. Results: Median age was 53 years and median support was 603 days. At data cutoff, 149 patients remained alive on support, eight underwent transplantation, and 58 died on support. At 5 years, the cumulative incidences of on-device death and heart transplantation were 35.3% and 4.1%, respectively, with no significant age-group difference (Fine–Gray global p = 0.088). In the secondary transplant-censored Kaplan–Meier analysis, estimated survival was 87.4% at 30 days, 81.1% at 1 year, and 63.8% at 5 years. Higher preoperative creatinine was associated with mortality (HR, 1.93 per 1-mg/dL increase; 95% CI, 1.07–3.50; p = 0.029). No intrinsic pump thrombosis occurred. Conclusions: HeartMate 3 provided durable support with favorable long-term survival, although non-pump adverse events remained clinically relevant.
Open AccessA Decade of Durable Mechanical Circulatory Support with HeartMate 3 Across Age Groups in a Single-Center Experience
Background: Long-term real-world data after HeartMate 3 implantation remain limited, particularly regarding age-specific outcomes. We evaluated on-device survival and major adverse events across nearly a decade of experience. Methods: This retrospective single-center study included 215 patients undergoing primary HeartMate 3 implantation between January 2016 and October 2025. On-device mortality was analyzed using Aalen–Johansen cumulative incidence estimates with heart transplantation as a competing event; age-group differences were assessed using Fine–Gray regression. Transplant-censored Kaplan–Meier survival was examined secondarily, and mortality predictors were evaluated using multivariable Cox regression. Results: Median age was 53 years and median support was 603 days. At data cutoff, 149 patients remained alive on support, eight underwent transplantation, and 58 died on support. At 5 years, the cumulative incidences of on-device death and heart transplantation were 35.3% and 4.1%, respectively, with no significant age-group difference (Fine–Gray global p = 0.088). In the secondary transplant-censored Kaplan–Meier analysis, estimated survival was 87.4% at 30 days, 81.1% at 1 year, and 63.8% at 5 years. Higher preoperative creatinine was associated with mortality (HR, 1.93 per 1-mg/dL increase; 95% CI, 1.07–3.50; p = 0.029). No intrinsic pump thrombosis occurred. Conclusions: HeartMate 3 provided durable support with favorable long-term survival, although non-pump adverse events remained clinically relevant.
- Open Access
Sutureless Aortic Valve Replacement with the Perceval Plus® Versus TAVI: A Propensity-Matched Analysis of Postoperative Outcomes, Hematological Dynamics, and Inflammatory Response
Perceval Plus and TAVI are increasingly used for severe aortic stenosis, both relying on a self-expanding nitinol stent design, yet evidence specific to Perceval Plus remains limited regarding postoperative clinical outcomes and hematological and inflammatory dynamics. We compared postoperative clinical outcomes and longitudinal platelet/CRP dynamics between Perceval Plus and TAVI in a retrospective single-center cohort, in which 26 propensity score-matched pairs were obtained (1:1 matching) from patients undergoing Su-AVR (Perceval Plus, n = 53) or TAVI (self-expanding Medtronic devices, n = 101). Mortality, echocardiographic outcomes, and rates of postoperative atrial fibrillation and conduction disturbances showed no statistically significant differences between groups, while TAVI was associated with shorter ICU and hospital stay and Su-AVR required higher FFP transfusion (p = 0.016). Platelet count declined in both groups, with a deeper nadir in Su-AVR (postoperative day 3: 66% decline) versus TAVI (day 4: 27% decline), with a significant group × time interaction (p = 0.013); CRP rose in both groups but more rapidly and to a greater magnitude in Su-AVR (time and group × time interaction, both p < 0.001). Su-AVR and TAVI showed no statistically significant differences in the clinical safety outcomes assessed but differed in postoperative hematological and inflammatory magnitude, likely reflecting multifactorial procedure- and device-related mechanisms, warranting confirmation in larger, prospective, multicenter studies.
Open AccessSutureless Aortic Valve Replacement with the Perceval Plus® Versus TAVI: A Propensity-Matched Analysis of Postoperative Outcomes, Hematological Dynamics, and Inflammatory Response
Perceval Plus and TAVI are increasingly used for severe aortic stenosis, both relying on a self-expanding nitinol stent design, yet evidence specific to Perceval Plus remains limited regarding postoperative clinical outcomes and hematological and inflammatory dynamics. We compared postoperative clinical outcomes and longitudinal platelet/CRP dynamics between Perceval Plus and TAVI in a retrospective single-center cohort, in which 26 propensity score-matched pairs were obtained (1:1 matching) from patients undergoing Su-AVR (Perceval Plus, n = 53) or TAVI (self-expanding Medtronic devices, n = 101). Mortality, echocardiographic outcomes, and rates of postoperative atrial fibrillation and conduction disturbances showed no statistically significant differences between groups, while TAVI was associated with shorter ICU and hospital stay and Su-AVR required higher FFP transfusion (p = 0.016). Platelet count declined in both groups, with a deeper nadir in Su-AVR (postoperative day 3: 66% decline) versus TAVI (day 4: 27% decline), with a significant group × time interaction (p = 0.013); CRP rose in both groups but more rapidly and to a greater magnitude in Su-AVR (time and group × time interaction, both p < 0.001). Su-AVR and TAVI showed no statistically significant differences in the clinical safety outcomes assessed but differed in postoperative hematological and inflammatory magnitude, likely reflecting multifactorial procedure- and device-related mechanisms, warranting confirmation in larger, prospective, multicenter studies.